Kiniksa Pharmaceuticals (NASDAQ:KNSA) Lowered to “Buy” at ValuEngine

Share on StockTwits

ValuEngine cut shares of Kiniksa Pharmaceuticals (NASDAQ:KNSA) from a strong-buy rating to a buy rating in a report published on Wednesday morning, ValuEngine reports.

KNSA has been the topic of a number of other reports. Zacks Investment Research lowered Kiniksa Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, January 1st. Goldman Sachs Group raised Kiniksa Pharmaceuticals from a neutral rating to a buy rating and upped their price objective for the stock from $16.00 to $18.00 in a research report on Friday, December 6th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $21.75.

Shares of KNSA stock traded up $0.52 during trading hours on Wednesday, hitting $15.26. 9,407 shares of the company were exchanged, compared to its average volume of 307,087. Kiniksa Pharmaceuticals has a 52 week low of $5.01 and a 52 week high of $25.79. The business has a 50 day moving average of $12.18 and a two-hundred day moving average of $10.24. The company has a market capitalization of $806.74 million, a PE ratio of -4.30 and a beta of -0.95.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings data on Monday, October 28th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.23. As a group, sell-side analysts forecast that Kiniksa Pharmaceuticals will post -2.99 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the company. Citadel Advisors LLC lifted its position in shares of Kiniksa Pharmaceuticals by 195.8% in the second quarter. Citadel Advisors LLC now owns 372,287 shares of the company’s stock worth $5,041,000 after purchasing an additional 246,442 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Kiniksa Pharmaceuticals by 14.4% during the 2nd quarter. BlackRock Inc. now owns 1,107,091 shares of the company’s stock worth $14,990,000 after buying an additional 139,072 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in shares of Kiniksa Pharmaceuticals by 300.0% in the 3rd quarter. Point72 Asset Management L.P. now owns 140,000 shares of the company’s stock valued at $1,191,000 after acquiring an additional 105,000 shares in the last quarter. First Manhattan Co. grew its holdings in shares of Kiniksa Pharmaceuticals by 68.3% in the 2nd quarter. First Manhattan Co. now owns 63,976 shares of the company’s stock valued at $866,000 after acquiring an additional 25,970 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of Kiniksa Pharmaceuticals by 17.1% in the second quarter. Northern Trust Corp now owns 154,899 shares of the company’s stock valued at $2,097,000 after acquiring an additional 22,645 shares during the last quarter. 29.85% of the stock is owned by institutional investors.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.

Read More: Initial Coin Offerings entail a high degree of risk

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.